WHAT HAPPENED IN EACH STUDY
TB-500 Research Findings: Animals First, Claims Second
Studies looked at wounds, hearts, stroke, muscle, and hair. Animals got the intact protein in most tests. Human claims go farther than the results.
What thymosin beta-4 changes before TB-500 is discussed
Most TB-500 claims began with studies of thymosin beta-4. The full protein has forty-three linked parts and is found in many human cells [5]. Blood platelets and immune cells release it near an injury.
A review found that thymosin beta-4 holds actin and helps cells move [5]. It may also limit scars, swelling, and cell death. New blood vessels can grow as well.
Those effects may aid repair, but they may also bring risk. TB-500 carries only the actin-holding part. In people, the short chain has not produced equal results in a sound test [10]. That gap matters when you weigh a claim.
What TB-500 benefits claims leave out
A rat wound study used full thymosin beta-4, not the seven-part chain. New skin covered 42% more after four days and 61% more after seven days. The open wound became at least 11% smaller as its edges pulled together [7]. More collagen, which helps support skin, and new blood vessels also formed.
Another rat study found better healing in a knee ligament after thymosin beta-4 [5]. Rodent work with thymosin beta-4 also found faster hair growth [5]. None of these thymosin beta-4 studies tested the short chain on your injury.
In 2026, a Sports Medicine review checked this class of unapproved peptides [11]. It found that animal repair claims ran well ahead of human safety proof. That's a fair verdict on these results.
What researchers try to change with TB-500
Studies of thymosin beta-4 in lab-grown cells and in animals looked at wounds, scars, hearts, and stroke [5]. They also checked new blood vessels and cell motion. Those results sit behind the repair claims.
The seven-part chain hasn't shown a human benefit [10]. Interest in TB-500 rests on its actin-holding stretch [1]. Cell motion may change, but that isn't the same as healing you.
The TB-500 amounts used in research page lists what those tests gave. The figures belong to the animals or full protein studied. They don't set a plan for you.
What TB-500 wound claims come from
A rat study used full thymosin beta-4 on deep wounds. New skin coverage rose 42% by day four and up to 61% by day seven [7]. The wound edges pulled closer together. Collagen increased too.
A lab-made actin-holding chain helped wounds in diabetic and old mice [3]. That animal result is useful. It doesn't establish wound healing for people [10].
What TB-500 studies don't tell you about timing
No study gives a human healing timetable for the short chain [10]. A rat study used full thymosin beta-4 on deep wounds. New skin coverage rose 42% by day four and up to 61% by day seven [7].
Those days came from rats given the full protein. The seven-part chain was not tested. You can't turn rat dates into your schedule. A human claim that borrows them is borrowing too much.
What TB-500 heart claims get right and wrong
In rodents, researchers closed a heart artery and then gave full thymosin beta-4. Fewer heart cells died, and cell motion rose. The animals' hearts also worked better [6].
A pig study did not find less heart damage from full thymosin beta-4. The animal findings therefore disagree. Neither experiment answers what the short chain might do to your heart.
What TB-500 stroke claims borrow from rats
A rat stroke study gave thymosin beta-4 into the belly. At 2 and 12 milligrams for every kilogram of the rat's weight, the animals moved better. The change ran from day 14 through day 56 [8].
Rats given 18 milligrams for every kilogram showed no clear help. The authors estimated that 3.75 milligrams for every kilogram might bring the largest change. That figure came from their math, not from a group that got that exact amount. Another rat report found better movement after stroke [9].
Both tests concerned the intact protein. You can't apply those rat results to yourself. The results also warn that more isn't always better.
What blood-vessel growth may mean for TB-500
Thymosin beta-4 helped cells from the lining of blood vessels move [5]. It also helped new vessels form. A wound may use that fresh blood supply.
Tumors can use new vessels as well. New vessel growth isn't plainly good or bad. It is one reason the cancer question remains open for you.
What TB-500 muscle claims miss about strength
Young muscle cells moved toward injured tissue when thymosin beta-4 was present. A mouse study then tested 150 micrograms. Researchers gave it twice a week over six months. More muscle fibers began to regrow.
Yet the mice gained no strength. Their hearts and thick scar tissue didn't improve either. Human recovery research hasn't tested the short chain [10]. More new muscle fibers did not mean more strength.
What TB-500 may change about swelling
In 2024, cells in a dish released less IL-8, a substance that helps drive swelling [12]. Full thymosin beta-4 was tested. The seven-part chain wasn't. This doesn't show that your sore joint would hurt less.
What TB-500 hair claims leave out
Very tiny amounts of thymosin beta-4 woke up stem cells near hair roots [5]. Rats and mice then grew hair faster. The tested substance was the full protein.
TB-500 was not shown to grow hair on you. Animal hair is a start, not a human answer. A sales page may forget that second sentence.
What TB-500 studies don't settle about cancer
Some cancers found in the pancreas or colon have high amounts of thymosin beta-4. In lab work, the protein was tied to spreading cancer and feeding tumors with new blood vessels [5]. Those same jobs may help a wound.
The concern makes sense, but its size is unknown. No study gives your chance of harm. Cancer is a real open question, not a proved outcome.
What may go wrong with TB-500
Human safety work on TB-500 hasn't used a comparison group [10]. The main concern involves cell motion and new blood vessels feeding a tumor. A wound may benefit from those vessels, but a tumor may too [5]. We don't know the size of that risk.
In 2026, a Sports Medicine review warned that unapproved peptides may cause serious harm [11]. Many are used outside normal drug checks. The sports ban is separate and clear: tested athletes can't use the substance.
The vial adds another unknown. It may hold the wrong chain, the wrong amount, or unwanted material. That makes any reaction hard to explain.
The rat stroke study gives a blunt lesson: results improved at 2 and 12 milligrams per kilogram of body weight. Rats at 18 milligrams per kilogram did not improve [8]. More wasn't better. Claims about starting high and then using less have no sound human study behind them.
What remains unknown about TB-500 side effects
A human comparison group hasn't supplied side-effect rates for the short chain [10]. Cell motion and new blood vessels feeding a tumor are the main concern [5]. Those jobs may aid repair, yet may also aid a tumor.
A research vial adds another doubt. It may hold the wrong chain, unwanted material, or the wrong amount. No honest review can give you a sound rate for harm.
Is TB-500 Safe? What the human study did and didn't test
A finished human safety study of the seven-part TB-500 chain does not exist [10]. Human safety work gave adults full thymosin beta-4 instead. In that Phase 1 study, some got a placebo for comparison. The 40 healthy adults received up to 1260 mg through a vein [10].
The adults handled the tested amount without serious harm. The short chain was absent from the test. Its safety by any route remains unknown to you.
How human trials left TB-500 untested
A finished comparison trial of TB-500 in people does not exist [10]. Human studies used full thymosin beta-4 instead. A Phase 1 vein study looked for harm and tracked thymosin beta-4 through the body. Dry-eye studies used drops of that protein called RGN-259 [10].
Other shots of thymosin beta-4 were listed for stroke and heart attack. One early shot study was withdrawn before it began, so it produced no results. The human work is much thinner than a brochure may suggest.
What TB-500 ligament claims rest on
One rat study found better healing in a medial collateral knee ligament after thymosin beta-4 [5]. That is one of the few direct findings about a ligament. It helps explain the athletic interest.
The test didn't use the small chain, and it didn't include people [10]. The finding belongs to rats given the whole protein. It does not answer whether your tendon or ligament will mend faster.
What separates TB-500 from BPC-157 in the studies
The two are different research peptides. TB-500 copies the actin-holding part of thymosin beta-4 [1]. The other peptide comes from a different line of research.
A 2026 Sports Medicine review found too little human safety work for both [11]. Neither is approved for human use. Putting the names side by side doesn't make the proof stronger.
Research context and clinical access
Keep the evidence question separate from the access question
TB-500 is discussed here as a research subject rather than a treatment recommendation; TB-500 prescription-access questions can reach licensed telehealth review at mypromise.com through Promise Peptides, where clinician review replaces self-directed medical decisions.
What TB-500 and BPC-157 do not prove together
TB-500 and BPC-157 are separate peptides. TB-500 carries the actin-holding part of thymosin beta-4. That grip may alter cell movement [1][2].
BPC-157 is a 15-amino-acid chain, meaning it has fifteen parts, and has its own studies. This page doesn't borrow those results. A claim that the pair works well needs a test of both.
FDA has discussed both names as substances a pharmacy might use to make drugs. That discussion did not approve either one. A 2026 Sports Medicine paper found too little human safety work for both [11]. Researchers haven't compared the pair in people, so you can't rank or combine them from sound proof.